[PAGID] Candidiasis and cellular dysfunction in a previously healthy adult

Richard L. Wasserman rich.wasserman at dallasallergy.net
Tue Dec 2 23:28:04 EST 2008


I'd very much appreciate comments and suggestions for further work up of
this patient.
Richard Wasserman
Dallas

The case:
I saw a 32 yo woman with candida esophagitis. She had been completely
well until several months after the birth of her second child when she
developed malaise, fatigue and non-specific GI symptoms of bloating,
abdominal pain and intermittent diarrhea. She has lost more than 10% of
her body weight and is significantly below her pre-pregnant weight. She
has been on a high calorie diet and continues to loose weight. She has
had an extensive GI evaluation including EGD, colonoscopy and capsule
study; all normal. There have been no other infections (no significant
infection history ever), no signs nor symptoms of collagen vascular
disease. Her studies of cellular immunity are:


Abs.CD19+ Lymphs 245 /uL 12-645
Absolute CD 3 1433 /uL 622-2402
Absolute CD 4 Helper 1053 /uL 359-1519
Abs. CD 8 Suppressor 326 /uL 109-897
% CD19+ Lymphs 13.6 % 3.3-25.4
% CD 3 Pos. Lymph. 79.6 % 57.5-86.2
% CD 4 Pos. Lymph. 58.5 % 30.8-58.5
% CD 8 Pos. Lymph. 18.1 % 12.0-35.5
CD4/CD8 Ratio 3.23 0.92-3.72
WBC 5.4 x10E3/uL 4.0-10.5
Hemoglobin 13.0 g/dL 11.5-15.0
Neutrophils 56 % 40-74
Lymphs 34 % 14-46
Monocytes 8 % 4-13
Eos 1 % 0-7
Basos 1 % 0-3
Tests: (3) Lymphocyte Activation (826963)
Unstimulated CD4 12 ng/mL
PHA - CD4 Activation [L] 119 ng/mL >225 Normal
activation of CD4 cells is indicated if the
patient's responses reach the threshold or
reference value shown. The cellular immune
response to PHA stimulation can be categorized as
follows:
ng/mL of ATP Interpretation
<226 Low Immune Cell Response
226-524 Moderate Immune Cell Response
>524 Strong or High Level of Immune Cell Response

Tests: (4) Tetanus toxoid-CD4 Activation (827140)
Tetanus toxoid-CD4 Act.*
[L] 10 ng/mL >23
This test was developed and its performance

characteristics determined by IBT Reference Lab.
It has not been cleared or approved by the FDA.
**Effective October 29, 2008 this panel will be**
non orderable. For replacement number, please
contact your local LabCorp Representative.
placement number, please contact
your local LabCorp Representative.

Tests: (5) Concanavalin A(CON A)-CD4 Act. (827144)
Concanaval A (Con-A)-CD4 Act.*
189 ng/mL >136
This test was developed and its performance
characteristics determined by IBT Reference Lab.
It has not been cleared or approved by the FDA.

Tests: (6) Varicella-Zoster-CD4 Act. (827138)
Varicella-Zoster-CD4 Act.*
[L] 14 ng/mL >22
This test was developed and its performance
characteristics determined by IBT Reference Lab.
It has not been cleared or approved by the FDA.

Tests: (7) Candida albicans-CD4 Act. (827134)
Candida albicans-CD4 Act.*
[L] 13 ng/mL >25
This test was developed and its performance
characteristics determined by IBT Reference Lab.
It has not been cleared or approved by the FDA.

Tests: (8) ANA w/Reflex if Positive (164863)
! Antinuclear Antibodies Direct
38 AU/mL 0-99
Negative <100
Equivocal 100 - 120
Positive >120



Tests: (9) Sedimentation Rate-Westergren (005215)
Sedimentation Rate-Westergren 5 mm/hr 0-20
Tests: (10) C-Reactive Protein, Quant (006627)
C-Reactive Protein, Quant 2.7 mg/L 0.0-4.9
-------------- next part --------------
A non-text attachment was scrubbed...
Name: rich_wasserman.vcf
Type: text/x-vcard
Size: 243 bytes
Desc: not available
Url : <http://seven.pairlist.net/mailman/private/pagid/attachments/20081202/7d6d9825/attachment-0001.vcf>


More information about the PAGID mailing list